

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number  
**WO 2005/040139 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/422**,  
31/42, C07D 263/48, 413/04, 413/14, A61P 37/00, 35/00,  
29/00

(21) International Application Number:  
PCT/IB2004/003698

(22) International Filing Date: 22 October 2004 (22.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/513,214 23 October 2003 (23.10.2003) US

(71) Applicants (for all designated States except US): **AB SCI-  
ENCE** [FR/FR]; 3, Avenue Georges V, F-75008 Paris (FR).  
**CENTRE NATIONAL DE LA RECHERCHE SCIEN-  
TIFIQUE (CNRS)** [FR/FR]; 3, rue Michel Ange, F-75016  
Paris (FR). **INSTITUT CURIE** [FR/FR]; 26, rue d'Ulm,  
F-75005 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MOUSSY, Alain**  
[FR/FR]; 22 bis, passage Dauphine, F-75006 Paris (FR).  
**WERMUTH, Camille** [FR/FR]; 3, rue de la Côte d'Azur,  
F-67100 Strasbourg (FR). **GRIERSON, David** [CA/FR];  
32, rue de la Bonne Aventure, F-78000 Versailles (FR).  
**BENJAHAD, Abdellah** [FR/FR]; 55-57, rue Diderot -  
Entrée 8, F-94500 Champigny-Sur-Marne (FR). **CROISY,**  
**Martine** [FR/FR]; 12, route de Limours, F-78720 Cernay  
La Ville (FR). **CIUFOLINI, Marco** [US/FR]; 16, rue  
de Créqui, F-69006 Lyon (FR). **GIETHLEN, Bruno**  
[FR/FR]; 39, Domaine de l'Ile, F-67400 Illkirch (FR).

(74) Agents: **MARTIN, Jean-Jacques** et al.; Cabinet Regim-  
beau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

#### Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,  
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,  
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG)


— as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for all designations  
— of inventorship (Rule 4.17(iv)) for US only

#### Published:

— with international search report

[Continued on next page]

(54) Title: 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS



(I)

(57) Abstract: The present invention relates to novel compounds selected from 2-aminoaryloxazoles of formula I that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.



(88) Date of publication of the international search report:  
13 October 2005

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*